PERIODIC SOLUTIONS BIFURCATING FROM A CURVE OF SINGULARITY OF THE JERK SYSTEM





Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease

Background: Late acute graft-versus-host disease (aGVHD) is a complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with little data regarding treatment and outcomes.There is no standard treatment for gastrointestinal (GI) late aGVHD, especially for steroid-refractory (SR) GI late aGVHD.Vedolizumab, a monoclonal antibody in

read more